CA2813849C - Secukinumab for use in the treatment of ankylosing spondylitis - Google Patents

Secukinumab for use in the treatment of ankylosing spondylitis Download PDF

Info

Publication number
CA2813849C
CA2813849C CA2813849A CA2813849A CA2813849C CA 2813849 C CA2813849 C CA 2813849C CA 2813849 A CA2813849 A CA 2813849A CA 2813849 A CA2813849 A CA 2813849A CA 2813849 C CA2813849 C CA 2813849C
Authority
CA
Canada
Prior art keywords
secukinumab
ankylosing spondylitis
treatment
antibody
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2813849A
Other languages
English (en)
French (fr)
Other versions
CA2813849A1 (en
Inventor
Shephard Mpofu
Hanno Richards
Karthinathan Thangavelu
Matthias Machacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2813849(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to CA3116725A priority Critical patent/CA3116725C/en
Publication of CA2813849A1 publication Critical patent/CA2813849A1/en
Application granted granted Critical
Publication of CA2813849C publication Critical patent/CA2813849C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CA2813849A 2010-11-05 2011-11-04 Secukinumab for use in the treatment of ankylosing spondylitis Active CA2813849C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3116725A CA3116725C (en) 2010-11-05 2011-11-04 Secukinumab for use in the treatment of psoriatic arthritis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41053310P 2010-11-05 2010-11-05
US61/410,533 2010-11-05
PCT/EP2011/069476 WO2012059598A2 (en) 2010-11-05 2011-11-04 Methods of treating rheumatoid arthritis using il-17 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3116725A Division CA3116725C (en) 2010-11-05 2011-11-04 Secukinumab for use in the treatment of psoriatic arthritis

Publications (2)

Publication Number Publication Date
CA2813849A1 CA2813849A1 (en) 2012-05-10
CA2813849C true CA2813849C (en) 2021-06-15

Family

ID=44906168

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2813849A Active CA2813849C (en) 2010-11-05 2011-11-04 Secukinumab for use in the treatment of ankylosing spondylitis
CA3116725A Active CA3116725C (en) 2010-11-05 2011-11-04 Secukinumab for use in the treatment of psoriatic arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3116725A Active CA3116725C (en) 2010-11-05 2011-11-04 Secukinumab for use in the treatment of psoriatic arthritis

Country Status (31)

Country Link
US (11) US9744234B2 (enExample)
EP (6) EP4116325B1 (enExample)
JP (8) JP2014503482A (enExample)
KR (5) KR20150020734A (enExample)
CN (2) CN103189074A (enExample)
AU (1) AU2011325134B2 (enExample)
BR (1) BR112013011176A2 (enExample)
CA (2) CA2813849C (enExample)
CL (1) CL2013001213A1 (enExample)
CY (1) CY1121802T1 (enExample)
DE (1) DE20187001T1 (enExample)
DK (2) DK3111954T3 (enExample)
ES (3) ES2804624T3 (enExample)
FI (1) FI3757126T3 (enExample)
HR (2) HRP20251174T1 (enExample)
HU (1) HUE044038T2 (enExample)
IL (4) IL311014A (enExample)
LT (2) LT3757126T (enExample)
MA (1) MA34647B1 (enExample)
MX (1) MX362591B (enExample)
PH (1) PH12013500890A1 (enExample)
PL (1) PL3111954T3 (enExample)
PT (2) PT3757126T (enExample)
RS (1) RS67377B1 (enExample)
RU (1) RU2582937C2 (enExample)
SG (2) SG10201505624VA (enExample)
SI (2) SI3757126T1 (enExample)
SM (1) SMT202500423T1 (enExample)
TR (1) TR201909531T4 (enExample)
TW (3) TWI616204B (enExample)
WO (1) WO2012059598A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
RU2665954C1 (ru) 2010-10-08 2018-09-05 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
KR20220116585A (ko) 2011-10-11 2022-08-23 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
CN105899231A (zh) * 2013-10-22 2016-08-24 诺夫免疫股份有限公司 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物
JP2017508446A (ja) * 2014-01-28 2017-03-30 北京韓美薬品有限公司 二機能性融合タンパク質及びその製造方法並びに使用
EP3142751B1 (en) 2014-05-13 2019-08-07 MedImmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA2949236C (en) 2014-05-15 2023-06-13 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3021976B1 (fr) * 2014-06-06 2018-11-02 Hospices Civils De Lyon Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
US20160002326A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US11278618B2 (en) 2014-09-10 2022-03-22 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
JP6675394B2 (ja) * 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
HK1247622A1 (zh) 2015-03-02 2018-09-28 180 Therapeutics Lp 利用il-33拮抗剂来治疗局部纤维化的方法
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
JP6858766B2 (ja) * 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2019534240A (ja) * 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
WO2019087133A1 (en) * 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
JP7596261B2 (ja) * 2018-09-26 2024-12-09 ビエラ バイオ インコーポレイテッド Ｃｄ４０ｌアンタゴニスト及びその使用
CN118453606A (zh) * 2019-01-22 2024-08-09 豪夫迈·罗氏有限公司 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CN115515610A (zh) * 2019-08-05 2022-12-23 伊夫罗生物科学公司 使用栖组织普雷沃菌治疗银屑病和特应性皮炎的组合物和方法
CA3155108A1 (en) * 2019-09-20 2021-03-25 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
JP2023502103A (ja) 2019-11-19 2023-01-20 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
EP4251197A4 (en) * 2020-11-25 2024-10-23 Dr. Reddy's Laboratories Ltd. STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MANUFACTURE THEREOF
WO2022144023A1 (zh) * 2021-01-04 2022-07-07 江苏恒瑞医药股份有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
KR102339377B1 (ko) * 2021-03-29 2021-12-13 김지혜 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치
CN117500834A (zh) * 2021-06-21 2024-02-02 百时美施贵宝公司 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
AU2024353756A1 (en) * 2023-09-27 2026-05-07 Samsung Bioepis Co., Ltd. Stable liquid formulation of anti-il-17 antibody

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
MXPA04004459A (es) 2001-11-09 2005-05-16 Johnson & Johnson Composiciones liofilizadas de anticuerpo monoclonal.
US7332276B2 (en) 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP3936365B2 (ja) 2004-09-14 2007-06-27 ソニーケミカル＆インフォメーションデバイス株式会社 機能素子実装モジュール及びその製造方法
LT2620450T (lt) 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1957474A4 (en) 2005-11-04 2011-08-24 Harvard College SYNTHESIS OF FTSZ HEMMERN
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
JPWO2008029908A1 (ja) 2006-09-07 2010-01-21 協和発酵キリン株式会社 抗体を含有する安定な凍結乾燥医薬製剤
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
EA200901031A1 (ru) 2007-02-02 2010-04-30 Новартис Аг Модуляторы склеростин-связывающих партнеров для лечения костных расстройств
KR101123487B1 (ko) 2007-03-20 2012-03-23 일라이 릴리 앤드 캄파니 항?스클레로스틴 항체
MX2009010179A (es) 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
JP5237366B2 (ja) * 2007-06-20 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 炎症性関節疾患に対する抗ｉｌ−１７ａ治療のための関節破壊のバイオマーカー
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP2011506483A (ja) 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
FR2938547B1 (fr) 2008-11-14 2012-11-16 Total Raffinage Marketing Liant synthetique clair
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
RU2665954C1 (ru) 2010-10-08 2018-09-05 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
KR20140097178A (ko) 2011-11-21 2014-08-06 노파르티스 아게 IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
KR20150010709A (ko) 2012-04-20 2015-01-28 노파르티스 아게 Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
JP6858766B2 (ja) 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Also Published As

Publication number Publication date
US20220193234A1 (en) 2022-06-23
TW201306864A (zh) 2013-02-16
KR20160067984A (ko) 2016-06-14
TW201726170A (zh) 2017-08-01
US12465635B2 (en) 2025-11-11
TWI616204B (zh) 2018-03-01
JP6049843B2 (ja) 2016-12-21
HRP20191162T1 (hr) 2019-10-04
LT3111954T (lt) 2019-07-10
CN103189074A (zh) 2013-07-03
SG10201505624VA (en) 2015-09-29
EP3111954A1 (en) 2017-01-04
KR20140008305A (ko) 2014-01-21
ES2733712T3 (es) 2019-12-02
TR201909531T4 (tr) 2019-07-22
MX362591B (es) 2019-01-25
PT3111954T (pt) 2019-07-10
JP2014503482A (ja) 2014-02-13
DK3757126T3 (da) 2025-09-29
JP2023109910A (ja) 2023-08-08
BR112013011176A2 (pt) 2020-09-01
PL3111954T3 (pl) 2019-10-31
ES2804624T1 (es) 2021-02-08
US20230293683A1 (en) 2023-09-21
IL282625A (en) 2021-06-30
IL225309A0 (en) 2013-06-27
US20130209480A1 (en) 2013-08-15
US10363307B2 (en) 2019-07-30
IL225309B (en) 2021-05-31
JP6250109B2 (ja) 2017-12-20
EP3542820A1 (en) 2019-09-25
DE20187001T1 (de) 2021-04-01
CN104800844A (zh) 2015-07-29
MA34647B1 (fr) 2013-11-02
US20260077042A1 (en) 2026-03-19
TWI604851B (zh) 2017-11-11
EP3757126A1 (en) 2020-12-30
WO2012059598A2 (en) 2012-05-10
SI3111954T1 (sl) 2019-08-30
US12594333B2 (en) 2026-04-07
SI3757126T1 (sl) 2025-12-31
RS67377B1 (sr) 2025-11-28
US20210177966A1 (en) 2021-06-17
DK3111954T3 (da) 2019-07-15
WO2012059598A3 (en) 2012-09-27
CA3116725A1 (en) 2012-05-10
JP2018065826A (ja) 2018-04-26
TW201517917A (zh) 2015-05-16
MX2013005060A (es) 2013-06-28
EP2635303A2 (en) 2013-09-11
JP2017002064A (ja) 2017-01-05
US20230346926A1 (en) 2023-11-02
FI3757126T3 (fi) 2025-10-12
CA3116725C (en) 2023-10-24
EP4116325B1 (en) 2026-04-01
US20180008706A1 (en) 2018-01-11
CL2013001213A1 (es) 2014-03-28
HUE044038T2 (hu) 2019-09-30
ES2804624T3 (en) 2026-01-23
CA2813849A1 (en) 2012-05-10
PT3757126T (pt) 2025-11-13
PH12013500890A1 (en) 2013-07-01
KR20180129991A (ko) 2018-12-05
CY1121802T1 (el) 2020-07-31
EP3912640A1 (en) 2021-11-24
SMT202500423T1 (it) 2026-01-12
RU2582937C2 (ru) 2016-04-27
HRP20251174T1 (hr) 2025-11-21
EP3912640B1 (en) 2025-03-05
US20190307880A1 (en) 2019-10-10
KR20180019247A (ko) 2018-02-23
ES3030036T3 (en) 2025-06-26
KR20150020734A (ko) 2015-02-26
LT3757126T (lt) 2025-12-10
JP2016065094A (ja) 2016-04-28
IL262559B (en) 2022-06-01
EP3111954B1 (en) 2019-04-03
US9744234B2 (en) 2017-08-29
RU2013125775A (ru) 2014-12-10
JP2025102772A (ja) 2025-07-08
JP2019142912A (ja) 2019-08-29
EP3757126B1 (en) 2025-09-03
JP6515168B2 (ja) 2019-05-15
SG189138A1 (en) 2013-05-31
AU2011325134A1 (en) 2013-04-04
IL311014A (en) 2024-04-01
IL262559A (en) 2018-12-31
US11534491B2 (en) 2022-12-27
EP4116325A1 (en) 2023-01-11
JP2021104995A (ja) 2021-07-26
US20250205332A1 (en) 2025-06-26
US20200276305A1 (en) 2020-09-03
TWI618543B (zh) 2018-03-21
US20210128726A1 (en) 2021-05-06
AU2011325134B2 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2012059598A3 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
EP4670788A3 (en) Methods of treating psoriasis using il-17 antagonists
CY1118014T1 (el) Aνti-il-23 αντισωματα
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EA201400579A1 (ru) Антитела к il-36r
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
PH12014500635B1 (en) Therapeutic peptides
EP2614085A4 (en) ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201290653A1 (ru) Состав антитела и терапевтические режимы
EA201401204A1 (ru) Антитела к il-23p19
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
WO2012103360A3 (en) Wnt compositions and methods of use thereof
MY159255A (en) Antigen binding proteins specific for serum amyloid p component
JO2991B1 (ar) بروتينات رابطة لمولد ضد المستقبل ايه للانترليوكين 17
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
WO2007007159A3 (en) Anti-madcam antibodies to treat uterine disorders
WO2007007160A3 (en) Anti-madcam antibodies to treat fever
TN2013000145A1 (en) Methods of treating psoriasis using il-17 antagonists
TN2013000144A1 (en) Methods of treating rheumatoid arthuritis using il-17 antagonists
AR124605A2 (es) Anticuerpos anti-il-36r

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161104

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241102

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241102

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250403

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250403

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250409

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250424

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250424

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023